/
PMVP
$1.29+$0.10 (+8.40%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$63.5M
53M shares
52-week range
$0.96 – $1.88
36% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.50%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-32.29
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $338.0K | $388.0K | $318.0K | $1.3M | $650.0K | $1.3M | $1.1M | $0 |
| Gross profit | −$338.0K | −$388.0K | −$318.0K | −$1.3M | −$650.0K | −$1.3M | −$1.1M | $0 |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $13.9M | $20.8M | $23.6M | $36.2M | $51.7M | $54.6M | $57.4M | $69.9M |
| Operating income | −$18.9M | −$26.6M | −$34.9M | −$58.3M | −$77.0M | −$80.1M | −$85.4M | −$86.2M |
| EBITDA | −$18.6M | −$25.0M | −$34.1M | −$56.5M | −$72.7M | −$67.7M | −$73.7M | −$79.8M |
| Net income | −$17.5M | −$25.4M | −$34.4M | −$57.8M | −$73.3M | −$69.0M | −$58.7M | −$77.7M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -5.80 | -0.59 | -2.40 | -1.28 | -1.61 | -1.44 | -1.14 | -1.48 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $3M | $-1.46 | $-1.55–$-1.37 | 2 |
| 2027 | $3M | $-1.12 | $-1.21–$-1.03 | 2 |
| 2028 | $24M | $-0.97 | $-0.97–$-0.97 | 1 |
| 2029 | $56M | $-0.79 | $-0.79–$-0.79 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.65
Price
$1.29
Implied downside
-49%
Peer comparison
PMV Pharmaceuticals, Inc
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.
www.pmvpharma.com- Employees
- 54
- IPO / List date
- Sep 25, 2020
- HQ
- PRINCETON, NJ
Held by traders on TradeandTell
No one on the platform currently holds PMVP.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in PMVP as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded PMVP yet.
